- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
| 12.03.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.03.2025 | 894 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.03.2025ISIN NameCA3719571018 GENESIS... ► Artikel lesen | |
| 12.03.25 | BenevolentAI: Result of Extraordinary General Meeting and Delisting from Euronext Amsterdam | 736 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that:
All resolutions proposed at its Extraordinary... ► Artikel lesen | |
| 12.03.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.03.2025 | 788 | Xetra Newsboard | Das Instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 12.03.2025 und ex Kapitalmassnahme am 13.03.2025 The instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY... ► Artikel lesen | |
| 06.02.25 | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 990 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 4,530 | +3,07 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 3,589 | +1,21 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
| ANAVEX LIFE SCIENCES | 4,399 | +2,59 % | ANAVEX LIFE SCIENCES CORP kurz vor dem entscheidenden Ausbruch | ||
| VERACYTE | 35,800 | +0,56 % | Veracyte, Inc.: Veracyte to Participate in Upcoming Investor Conferences | Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.
Wolfe Research Healthcare Conference New York... ► Artikel lesen | |
| ASCLETIS PHARMA | 1,460 | -0,68 % | Ascletis Pharma Inc.: Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development | - In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports... ► Artikel lesen | |
| BIOMEA FUSION | 1,365 | -1,09 % | Biomea Fusion, Inc. - 8-K, Current Report | ||
| JASPER THERAPEUTICS | 1,515 | -2,26 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria | 67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open... ► Artikel lesen | |
| ABSCI | 2,915 | +0,52 % | Absci Corp - 8-K, Current Report | ||
| LANTERN PHARMA | 3,400 | -5,03 % | Lantern Pharma Receives FDA Orphan Drug Designation For LP-284 | ||
| Y-MABS THERAPEUTICS | 8,610 | 0,00 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
| QIAGEN | 46,250 | -3,65 % | Qiagen-Aktie: Kommt jetzt die massive Übernahme? | Die Qiagen-Aktie schoss zuletzt massiv nach oben und setzt am Mittwoch ihre Aufwärtsbewegung fort. Dahinter stecken Übernahmegerüchte. Das müssen Anleger jetzt wissen. Neue Übernahmefantasie 2020 war... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,51 | +0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BIONTECH | 97,45 | +8,16 % | BioNTech-Aktie: Kommt jetzt der große Durchbruch? | Es sieht nach einer Trendwende bei der BioNTech-Aktie aus. Nachdem das Mainzer Biotech-Unternehmen 2025 eine ziemlich schwache Börsenperformance lieferte, zog der Aktienkurs in den ersten Tagen des... ► Artikel lesen | |
| ERASCA | 9,800 | -0,05 % | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 91,98 | +1,24 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence |
Das Unternehmen BENEVOLENTAI kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,087 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.